Exploring the Next Generation of Cancer Genomics at BSGM
News Sep 12, 2013
Oxford Gene Technology (OGT) is inviting delegates of the British Society for Genetic Medicine (BSGM) conference to join its seminar entitled “Genomic profiling of cancer - from aCGH to NGS” on Tuesday 17 September, 12.30-13.30.
Professor Bass Hassan, Professor of Medical Oncology at the University of Oxford, will be guest speaker at the seminar, where he will discuss his latest research: “Integrating NGS technology into a bench to bedside clinical programme in rare cancers”.
Professor Hassan is a close collaborator with OGT, whose expertise in genomic technologies is central to his research.
In a recent study working on the genomic characterization of a number of sarcoma cell lines, he benefited from OGT’s expertise in areas including targeted sequencing (exome and cancer panels), low-depth whole genome sequencing, RNA-Seq and aCGH.
As a “hot topic” in medical genetics, the seminar presents an ideal opportunity for researchers to hear more about the clinical application of NGS.
OGT’s microarray and sequencing products and services enable rapid access to meaningful, high-quality results. A range of cancer-specific options are available, including the SureSeq™ Solid Tumour Panel NGS Service and CytoSure arrays optimized for the rapid detection of CNV and LOH in haematological and solid tumours.
Delegates of BSGM conference can also visit booth 25, where they will not only have the chance to discuss how OGT can enhance their research, but can also enter into the prize draw to win an Amazon Kindle Fire Tablet.
CRISPR Used to Prevent Development of Angiogenesis of the RetinaNews
Powerful new technology may lead to novel therapies to prevent vision loss, blindness in those with diseases of the retina.READ MORE
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE
FDA Grants Full Approval to Blinatumomab for Acute Lymphoblastic LeukemiaNews
TheFDA has changed its accelerated approval of blinatumomab (Blincyto®) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.READ MORE
Comments | 0 ADD COMMENT
11th International Conference on Cancer Stem Cells
Jun 11 - Jun 13, 2018